Organization | Swedish Cancer Institute

Swedish Cancer Institute Report issue

Academic/Hospital Phase 2

Founded: Seattle WA United States (1910)

Organization Overview

First Clinical Trial

2003

NCT00066885

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Swedish Cancer Institute

Active Ingredients

Drugs in Phase 2 Trials (7)

calcitriol (rocaltrol) (1 trial)

docetaxel (taxotere) (1 trial)

everolimus (zortress) (1 trial)

rituximab (rituxan) (1 trial)

sorafenib (nexavar) (1 trial)

sunitinib (sutent) (1 trial)

tazemetostat (Tazverik) (2 trials)

Drugs in Other Trials (1)

alteplase (Activase) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Follicular (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 7
# of Trial APIs: 8